Today: 20 March 2026
Subscribe
Browse Category

NASDAQ:RVPH 24 October 2025 - 9 March 2026

Reviva Pharmaceuticals Holdings (RVPH) Starts 1-for-20 Reverse Split as Nasdaq Deadline Nears

Reviva Pharmaceuticals Holdings (RVPH) Starts 1-for-20 Reverse Split as Nasdaq Deadline Nears

Reviva Pharmaceuticals enacted a 1-for-20 reverse stock split early Monday to boost its share price and avoid a Nasdaq delisting. The company faces a March 27 deadline to meet the $1 minimum bid rule. Reviva is also seeking funding for a new Phase 3 trial of its schizophrenia drug after the FDA requested more data. Analyst Jason Kolbert downgraded the stock, citing unchanged fundamentals.
9 March 2026
·
Reviva Pharmaceuticals (RVPH) Stock Plunges After FDA Calls for Second Phase 3 Trial: News, Forecasts, and Analyst Takeaways on Dec. 24, 2025

Reviva Pharmaceuticals (RVPH) Stock Plunges After FDA Calls for Second Phase 3 Trial: News, Forecasts, and Analyst Takeaways on Dec. 24, 2025

Reviva Pharmaceuticals shares fell to $0.32 on December 24, 2025, after the FDA recommended a second Phase 3 trial for its schizophrenia drug brilaroxazine before a New Drug Application. The company said the new trial, RECOVER-2, could cost $60 million and delay potential approval to late 2028. Reviva plans to start the trial in the first half of 2026, pending financing.
24 December 2025
···
Reviva Pharmaceuticals (RVPH) Stock Today: Price, News, Forecast & Schizophrenia NDA Setup – 10 December 2025

Reviva Pharmaceuticals (RVPH) Stock Today: Price, News, Forecast & Schizophrenia NDA Setup – 10 December 2025

Reviva Pharmaceuticals (RVPH) traded around $0.69 per share mid-session December 10, up 10% on the day but still down 72% over the past year. Market cap stood near $78–80 million. On December 9, call options volume spiked 458% above average as traders speculated on upcoming catalysts. The company’s lead drug, brilaroxazine, recently completed Phase 3 trials in schizophrenia.
10 December 2025
··
Reviva Pharma Rockets 28% on Schizophrenia Trial Win – Analysts Eye 1000% Upside

Reviva Pharma Rockets 28% on Schizophrenia Trial Win – Analysts Eye 1000% Upside

RVPH shares closed at $0.57 on Oct 24 after a volatile month, swinging between $0.26 and $0.84. The stock surged 28% on Oct 23 following recent Phase 3 trial results for brilaroxazine and news of an upcoming FDA meeting. Reviva raised about $19 million this year to fund its CNS pipeline. Analyst targets average $6.25, implying a potential 1,000% upside.
24 October 2025
···

Stock Market Today

  • Schwab Fundamental International Large Company Index Sees $218.8M Inflow
    March 20, 2026, 11:42 AM EDT. The Schwab Fundamental International Large Company Index ETF (FNDF) experienced a notable inflow of approximately $218.8 million, marking a 1.0% increase in outstanding units week over week, rising from 442.3 million to 446.8 million units. Major holdings performance varied slightly, with Medtronic (MDT) and ZIM Integrated Shipping Services (ZIM) gaining 0.2% each, while Teva Pharmaceutical (TEVA) fell 1.8%. FNDF currently trades at $47.66, between its 52-week low of $31.915 and high of $52.935. ETF unit creation and destruction reflect buying and selling of underlying assets, influencing components' market activity.
Go toTop